Skip to main content
. Author manuscript; available in PMC: 2009 Sep 23.
Published in final edited form as: Hypertension. 2007 Nov 19;51(1):141–147. doi: 10.1161/HYPERTENSIONAHA.107.096552

Figure 3.

Figure 3

The relationship between log-transformed substance P degradation half-life and (A) DPPIV antigen and (B) APN activity during ACE inhibition. The relationship between bradykinin half-life and ACE activity in the absence (C) and presence (D) of an ACEi. Relationship between des-Arg9-bradykinin and (E) APP activity in the absence of ACE inhibition and (F) bradykinin half-life in the setting of ACE inhibition.